PMID- 20210241 OWN - NLM STAT- MEDLINE DCOM- 20100319 LR - 20221007 IS - 0300-8916 (Print) IS - 2038-2529 (Electronic) IS - 0300-8916 (Linking) VI - 95 IP - 6 DP - 2009 Nov-Dec TI - DNA/RNA markers for colorectal cancer risk in preserved stool specimens: a pilot study. PG - 753-61 AB - AIMS AND BACKGROUND: Exfoliated cells in human stool offer excellent opportunities to non-invasively detect molecular markers associated with colorectal tumorigenesis, and to evaluate the effects of exposures to exogenous and endogenous carcinogenic or chemopreventive substances. This pilot study investigated the feasibility of determining DNA methylation and RNA expression simultaneously in stool specimens treated with a single type of nucleic acid preservatives. METHODS: Stool specimens from 56 volunteers that were preserved up to a week with RNA later were used in this study. Bisulfite sequencing was used to determine methylation at 27 CpG loci on the estrogen receptor 1 (ESR1) promoter. Taqman assay was used for quantitative reverse transcription polymerase chain reactions to measure cyclooxygenase 2 (COX2) and epidermal growth factor receptor (EGFR) mRNA expression. Subjects' basic demographic and other selected risk factors for colorectal cancer were captured through questionnaires and correlated with the levels of these markers. RESULTS: Less than 10% of the samples failed in individual assays. Overall, 24.0% of the CpG loci on the ESR1 promoter were methylated. COX2 expression and alcohol use were positively correlated; an inverse association was present between EGFR expression and cigarette smoking; and subjects using anti-diabetic medication had higher ESR1 methylation. In addition, higher EGFR expression levels were marginally associated with history of polyps and family history of colorectal cancer. CONCLUSIONS: The present study demonstrates that simultaneous analyses for DNA and RNA markers are feasible in stool samples treated with a single type of nucleotide preservatives. Among several associations observed, the association between EGFR expression and polyps deserves further investigation as a potential target for colorectal cancer screening. Larger studies are warranted to confirm some of our observations. FAU - Kato, Ikuko AU - Kato I AD - Karmanos Cancer Institute, Wayne State University, 110 East Warren Avenue, Detroit, MI 48201, USA. katoi@karmanos.org FAU - Badsha, Kawsar Z AU - Badsha KZ FAU - Land, Susan AU - Land S FAU - Nechvatal, Jordan M AU - Nechvatal JM FAU - Matherly, Larry H AU - Matherly LH FAU - Tarca, Adi L AU - Tarca AL FAU - Majumdar, Adhip P AU - Majumdar AP FAU - Basson, Marc D AU - Basson MD FAU - Ram, Jeffrey L AU - Ram JL LA - eng GR - R01 AG014343/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Tumori JT - Tumori JID - 0111356 RN - 0 (Biomarkers, Tumor) RN - 0 (DNA, Neoplasm) RN - 0 (ESR1 protein, human) RN - 0 (Estrogen Receptor alpha) RN - 0 (RNA, Neoplasm) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 1.14.99.1 (PTGS2 protein, human) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Adult MH - Aged MH - Base Sequence MH - Biomarkers, Tumor/*genetics MH - Colorectal Neoplasms/chemistry/*genetics MH - CpG Islands/genetics MH - Cyclooxygenase 2/genetics MH - *DNA Methylation MH - DNA, Neoplasm/*analysis MH - ErbB Receptors/genetics MH - Estrogen Receptor alpha/genetics MH - Feasibility Studies MH - Feces/*chemistry MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Middle Aged MH - Molecular Sequence Data MH - Pilot Projects MH - RNA, Neoplasm/*analysis MH - Risk Assessment MH - Risk Factors MH - Sequence Analysis, DNA PMC - PMC4932904 MID - NIHMS796441 EDAT- 2010/03/10 06:00 MHDA- 2010/03/20 06:00 PMCR- 2016/07/05 CRDT- 2010/03/10 06:00 PHST- 2010/03/10 06:00 [entrez] PHST- 2010/03/10 06:00 [pubmed] PHST- 2010/03/20 06:00 [medline] PHST- 2016/07/05 00:00 [pmc-release] AID - 10.1177/030089160909500619 [doi] PST - ppublish SO - Tumori. 2009 Nov-Dec;95(6):753-61. doi: 10.1177/030089160909500619.